Human endometrial stromal decidualization is required for embryo receptivity, angiogenesis, and placentation. Previous studies from our laboratories established that connexin (Cx)-43 critically regulates endometrial stromal cell (ESC) differentiation, whereas gap junction blockade prevents it. The current study evaluated the plasticity of ESC morphology and Cx43 expression, as well as other biochemical markers of cell differentiation, in response to decidualizing hormones. Primary human ESC cultures were exposed to 10 nM estradiol, 100 nM progesterone, and 0.5 mM cAMP for up to 14 days, followed by hormone withdrawal for 14 days, mimicking a biphasic ovulatory cycle. Reversible differentiation was documented by characteristic changes in cell shape. Cx43 was reversibly up- and down-regulated after the estradiol, progesterone, and cAMP treatment and withdrawal, respectively, paralleled by fluctuations in prolactin, vascular endothelial growth factor, IL-11, and glycodelin secretion. Markers of mesenchymal-epithelial transition (MET), and its counterpart epithelial-mesenchymal transition, followed reciprocal patterns corresponding to the morphological changes. Incubation in the presence of 18α-glycyrrhetinic acid, an inhibitor of gap junctions, partially reversed the expression of decidualization and MET markers. In the absence of hormones, Cx43 overexpression promoted increases in vascular endothelial growth factor and IL-11 secretion, up-regulated MET markers, and reduced N-cadherin, an epithelial-mesenchymal transition marker. The combined results support the hypothesis that Cx43-containing gap junctions and endocrine factors cooperate to regulate selected biomarkers of stromal decidualization and MET and suggest roles for both phenomena in endometrial preparation for embryonic receptivity.
Pubmed ID: 27035651 RIS Download
Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.
This monoclonal targets Vimentin
View all literature mentionsThis monoclonal targets ZO-1 (D7D12) Rabbit mAb
View all literature mentionsThis monoclonal targets β-Catenin
View all literature mentionsThis unknown targets mouse IgG (H+L) F(ab')2 Fragment (Alexa Fluor 555 Conjugate)
View all literature mentionsThis unknown targets IgG (H+L)
View all literature mentionsThis monoclonal targets TCF8/ZEB1 (D80D3) Rabbit mAb
View all literature mentionsThis monoclonal targets CD10
View all literature mentionsThis monoclonal targets beta-actin
View all literature mentionsThis polyclonal targets Fibronectin
View all literature mentionsThis polyclonal secondary targets IgG (H+L)
View all literature mentionsThis polyclonal secondary targets IgG (H+L)
View all literature mentionsThis monoclonal targets E-Cadherin (24E10) Rabbit mAb
View all literature mentionsThis polyclonal targets Connexin 43
View all literature mentionsThis unknown targets Connexin 32
View all literature mentionsThis polyclonal targets Actin
View all literature mentionsThis monoclonal targets Actin
View all literature mentionsThis monoclonal targets Pan-Keratin (C11) Mouse mAb
View all literature mentions